Basel, March 27, 2023 — Novartis today announced positive topline results from an interim analysis of NATALEE, a Phase III trial evaluating Kisqali® (ribociclib) plus endocrine therapy (ET) in a broad ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback